As expected, the consumer healthcare segment and the neurosciences franchisee were adversely impacted by the pandemic, though the oncology franchisee provided the much needed resilience. Interestingly, management’s cost-saving initiatives helped expand the margin in H1. The advancement in the late-stage pipeline offers further upside sales potential for Cabometyx and Onivyde and could offset the impact of Somatuline’s generic erosion in the mid-term. The new CEO’s commercial
01 Aug 2020
Prudent cost management in H1; FY20 goals reinstated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prudent cost management in H1; FY20 goals reinstated
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
01 Aug 2020 -
Author:
Sumit Sayal -
Pages:
4
As expected, the consumer healthcare segment and the neurosciences franchisee were adversely impacted by the pandemic, though the oncology franchisee provided the much needed resilience. Interestingly, management’s cost-saving initiatives helped expand the margin in H1. The advancement in the late-stage pipeline offers further upside sales potential for Cabometyx and Onivyde and could offset the impact of Somatuline’s generic erosion in the mid-term. The new CEO’s commercial